CN117919214A - Penetration-promoting local anesthetic composition and preparation method and application thereof - Google Patents
Penetration-promoting local anesthetic composition and preparation method and application thereof Download PDFInfo
- Publication number
- CN117919214A CN117919214A CN202311825575.2A CN202311825575A CN117919214A CN 117919214 A CN117919214 A CN 117919214A CN 202311825575 A CN202311825575 A CN 202311825575A CN 117919214 A CN117919214 A CN 117919214A
- Authority
- CN
- China
- Prior art keywords
- composition
- menthol
- laurocapram
- lidocaine
- prilocaine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 52
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 239000003589 local anesthetic agent Substances 0.000 title abstract description 12
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims abstract description 34
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims abstract description 34
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 34
- 229940041616 menthol Drugs 0.000 claims abstract description 34
- 229960003639 laurocapram Drugs 0.000 claims abstract description 31
- 239000004480 active ingredient Substances 0.000 claims abstract description 21
- 239000003961 penetration enhancing agent Substances 0.000 claims abstract description 17
- WZSPWMATVLBWRS-UHFFFAOYSA-N 2-(diethylamino)-n-(2,6-dimethylphenyl)acetamide;n-(2-methylphenyl)-2-(propylamino)propanamide Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C.CCN(CC)CC(=O)NC1=C(C)C=CC=C1C WZSPWMATVLBWRS-UHFFFAOYSA-N 0.000 claims abstract description 16
- 238000002690 local anesthesia Methods 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 21
- 229960004194 lidocaine Drugs 0.000 claims description 17
- 238000003756 stirring Methods 0.000 claims description 15
- -1 polyoxyethylene Polymers 0.000 claims description 12
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 10
- 239000000839 emulsion Substances 0.000 claims description 10
- 239000011259 mixed solution Substances 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 claims description 10
- 229960001807 prilocaine Drugs 0.000 claims description 10
- 238000005303 weighing Methods 0.000 claims description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 8
- 229920002125 Sokalan® Polymers 0.000 claims description 8
- 229960001631 carbomer Drugs 0.000 claims description 8
- 239000004359 castor oil Substances 0.000 claims description 8
- 235000019438 castor oil Nutrition 0.000 claims description 8
- 239000003995 emulsifying agent Substances 0.000 claims description 8
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 8
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 7
- 206010002091 Anaesthesia Diseases 0.000 claims description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 6
- 230000037005 anaesthesia Effects 0.000 claims description 6
- 230000005496 eutectics Effects 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 239000000374 eutectic mixture Substances 0.000 claims description 5
- 238000002844 melting Methods 0.000 claims description 5
- 230000008018 melting Effects 0.000 claims description 5
- 230000001105 regulatory effect Effects 0.000 claims description 5
- 230000001502 supplementing effect Effects 0.000 claims description 5
- 230000008961 swelling Effects 0.000 claims description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- 239000003349 gelling agent Substances 0.000 claims description 3
- 229920001661 Chitosan Polymers 0.000 claims description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 229960003943 hypromellose Drugs 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 239000003002 pH adjusting agent Substances 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 238000001949 anaesthesia Methods 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 7
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 238000009776 industrial production Methods 0.000 abstract description 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 2
- 238000011160 research Methods 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 24
- 238000010521 absorption reaction Methods 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 210000003491 skin Anatomy 0.000 description 11
- 230000035515 penetration Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 230000001186 cumulative effect Effects 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 230000003444 anaesthetic effect Effects 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 229940019097 EMLA Drugs 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 229960001777 castor oil Drugs 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940052294 amide local anesthetics Drugs 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229940082484 carbomer-934 Drugs 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 231100000024 genotoxic Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 231100000435 percutaneous penetration Toxicity 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002691 topical anesthesia Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention belongs to the technical field of pharmaceutical preparations, and relates to a local anesthetic composition for promoting permeation, and a preparation method and application thereof. The composition for local anesthesia comprises: an active ingredient and a permeation enhancer; the active ingredients are lidocaine and prilocaine; the penetration enhancer is at least one of menthol and laurocapram; the mass ratio of the active ingredient to the penetration enhancer is 0.7-6.8:1. the invention is compounded by menthol and laurocapram according to a specific mass ratio, and the invention has synergistic effect, can promote the permeation of active ingredients, and further can exert the local anesthetic efficacy more quickly; and further through the specific mass ratio of menthol, laurocapram and active ingredients, the medicine permeation is further promoted, and the waiting time of patients is reduced. The invention has stable product quality and can meet the requirements of industrial production on the basis of ensuring quick local anesthesia effect through strict formula and process research.
Description
Technical Field
The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a local anesthesia composition for promoting permeation, and a preparation method and application thereof.
Background
Superficial surgery, etc. cause pain of superficial skin trauma and wettability of human body to different degrees, and anesthesia and analgesia are generally carried out clinically by adopting an anesthetic injection method, but the injection method causes various problems such as pain feeling, toxic and side effects on the body, etc. Therefore, to alleviate pain in patients, there is a need to develop a pharmaceutical formulation for local anesthesia that is not injectable, and that is applied directly to the skin surface.
Lidocaine and prilocaine belong to amide local anesthetics, have strong penetrating power, can be absorbed through skin or mucous membrane, reduce the generation of nerve impulse from the source to alleviate pain, and are clinically used for superficial preoperative local infiltration anesthesia of skin or mucous membrane parts. Currently, EMLA, li Bing bicaine cream, is widely used. The lidocaine can be degraded in vivo to generate genotoxic impurities, and can be used together with prilocaine to reduce the dosage of lidocaine and improve the safety, and can also form eutectic substances to improve the percutaneous permeability. However, the EMLA product has the anesthesia time of about 30min-60min, the drug effect exerting time is long, and the waiting time of patients is long.
The active ingredients in the external preparation need to be dissolved, released and penetrated through skin, and are transferred to the rear of the action target point through absorption and distribution to exert the drug effect, thereby achieving the purpose of treatment. The transdermal property of the active ingredient and factors such as the type and the dosage of the permeation enhancer added in the preparation can directly lead to the permeation performance, and the release and the permeation capability of the active ingredient directly influence the in-vivo absorption and distribution conditions of the medicine, so that the acting time and the acting strength are changed. At present, penetration enhancers commonly used in external preparations include propylene glycol, isopropyl myristate, menthol, and the like.
Xu Yingying et al studied the skin permeability of menthol and azone to lidocaine gel in "influence of penetration enhancer on lidocaine gel transdermal action" (China pharmacy, 2003,14,6), and found that 3% menthol has an obvious penetration-promoting effect on lidocaine gel, while azone has an insignificant penetration-promoting effect on lidocaine.
Chinese patent CN101209250A discloses a compound lidocaine emulsifiable paste and a preparation process, wherein the compound lidocaine emulsifiable paste consists of lidocaine, prilocaine, carbomer 934, azone, tween-80, 10% sodium hydroxide aqueous solution and water. The invention improves the percutaneous absorption rate, and the percutaneous penetration rate is about 30% more than that of EMLA in 1 hour.
Disclosure of Invention
In order to solve the technical problem of long anesthesia effective time in the prior art, the invention aims to provide a local anesthesia composition for promoting permeation, and a preparation method and application thereof.
In order to achieve the above purpose, the present invention adopts the following technical scheme:
the invention provides a local anesthetic composition, which comprises the following raw materials: an active ingredient and a permeation enhancer;
the active ingredients are lidocaine and prilocaine; the penetration enhancer is at least one of menthol and laurocapram.
Further, the mass ratio of the active ingredient to the penetration enhancer is 0.7-6.8:1.
Further, the mass ratio of the active ingredient to the penetration enhancer is 5:2.1.
Further, the permeation enhancer is menthol and laurocapram.
Further, the mass ratio of menthol to laurocapram is (0.02-0.35): (1.5-2.8).
Further, the mass ratio of menthol to laurocapram is 0.1:2.
Further, the weight percentage of lidocaine in the composition is 1-5%, the weight percentage of prilocaine in the composition is 1-5%, the weight percentage of menthol in the composition is 0.02-0.35%, and the weight percentage of laurocapram in the composition is 1.5-2.8%.
Further, the composition also comprises the following raw materials: emulsifying agent, gelatinizer, pH regulator and water.
Further, the composition consists of the following substances in percentage by weight: 1-5% of lidocaine, 1-5% of prilocaine, 0.02-0.35% of menthol, 1.5-2.8% of laurocapram, 1-3% of emulsifying agent, 0.5-2% of gelling agent, 0.5-5.0% of pH regulator and the balance of water.
Further, the emulsifier is at least one of polyoxyethylene hydrogenated castor oil, tween, span, polyoxyethylene stearate and polyoxyethylene cetostearyl ether.
Further, the gelling agent is at least one of carbomer, sodium carboxymethyl cellulose, hypromellose, methylcellulose, and chitosan.
Further, the pH adjuster is at least one of triethanolamine, triethylamine, ethylenediamine, sodium hydroxide, and sodium bicarbonate, which adjusts the pH of the composition to 8.5-10.
The invention also provides a preparation method of the composition, which comprises the following steps:
s1, weighing lidocaine and prilocaine, and melting to obtain a eutectic;
S2, weighing a gelatinizing agent, adding water, and stirring and swelling completely to obtain a mixed solution for later use;
S3, adding an emulsifier, menthol, laurocapram and water into the eutectic mixture in the step S1, and uniformly mixing to obtain emulsion for later use;
S4, adding the mixed solution and the pH regulator in the step S2 into the emulsion in the step S3, regulating the pH to 8.5-10, supplementing water, and uniformly mixing to obtain the composition.
The invention also provides application of the composition in preparing a local anesthetic drug.
The invention also provides a local anesthetic medicament comprising the composition.
Further, the composition or medicament is for cortical local anesthesia in the following cases: (1) needle penetration; (2) superficial surgery.
Further, the needle penetration includes catheterization and blood sample collection.
The beneficial effects of the invention are as follows:
The local anesthetic composition for promoting permeation is compounded by menthol and laurocapram according to a specific mass ratio, and has synergistic effect, so that permeation of active ingredients can be promoted, and further, the local anesthetic effect can be exerted more quickly; and further through menthol, laurocapram and specific mass ratio of active ingredients (lidocaine and prilocaine), the penetration of the medicine is further promoted, the local anesthesia is quickened to exert the medicine effect, and the waiting time of patients is reduced.
The invention has good stability, no obvious decrease of active ingredient content and stable product quality on the basis of ensuring quick drug effect of local anesthesia through strict formula and process research, and can meet the requirement of industrial production.
Detailed Description
Other advantages and effects of the present invention will become apparent to those skilled in the art from the following disclosure, which describes the embodiments of the present invention with reference to specific examples. The invention may be practiced or carried out in other embodiments that depart from the specific details, and the details of the present description may be modified or varied from the spirit and scope of the present invention.
Before the embodiments of the invention are explained in further detail, it is to be understood that the invention is not limited in its scope to the particular embodiments described below; it is also to be understood that the terminology used in the examples of the invention is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the invention.
Where numerical ranges are provided in the examples, it is understood that unless otherwise stated herein, both endpoints of each numerical range and any number between the two endpoints are significant both in the numerical range. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
The invention does not limit the sources of the adopted raw materials, and if no special description exists, the adopted raw materials are all common commercial products in the technical field.
Examples
Example 1
A composition for local anesthesia, which comprises the following substances in percentage by weight: 2.5% of lidocaine, 2.5% of prilocaine, 0.1% of menthol, 2% of laurocapram, 1.9% of polyoxyethylene hydrogenated castor oil, 1% of carbomer, and the balance of water, wherein the pH is adjusted to 9.2 by triethanolamine.
The preparation method of the composition comprises the following steps:
S1, weighing lidocaine and prilocaine according to a formula, and stirring and melting uniformly at 50-80 ℃ to obtain uniform and transparent liquid, namely eutectic;
S2, weighing carbomer and purified water with the formula amount of 50% according to the formula, standing overnight for swelling to obtain a mixed solution;
S3, adding polyoxyethylene hydrogenated castor oil, menthol and laurocapram with the formula amount into the eutectic mixture in the step S1, stirring and mixing uniformly, and mixing with purified water with the formula amount of 30% at 60-70 ℃ to obtain emulsion for later use;
And S4, adding the mixed solution obtained in the step S2 into the emulsion obtained in the step S3, stirring uniformly, regulating the pH of the solution to 9.2 by using triethanolamine, supplementing water, and stirring uniformly to obtain the composition.
Example 2
A composition for local anesthesia, which comprises the following substances in percentage by weight: 1% of lidocaine, 1% of prilocaine, 0.02% of menthol, 1.5% of laurocapram, 1% of polyoxyethylene hydrogenated castor oil, 0.5% of carbomer, and triethanolamine, wherein the pH is adjusted to 9.2, and the balance is water.
The preparation method of the composition comprises the following steps:
S1, weighing lidocaine and prilocaine according to a formula, and stirring and melting uniformly at 50-80 ℃ to obtain uniform and transparent liquid, namely eutectic;
S2, weighing carbomer and purified water with the formula amount of 50% according to the formula, standing overnight for swelling to obtain a mixed solution;
S3, adding polyoxyethylene hydrogenated castor oil, menthol and laurocapram with the formula amount into the eutectic mixture in the step S1, stirring and mixing uniformly, and mixing with purified water with the formula amount of 30% at 60-70 ℃ to obtain emulsion for later use;
And S4, adding the mixed solution obtained in the step S2 into the emulsion obtained in the step S3, stirring uniformly, regulating the pH of the solution to 9.2 by using triethanolamine, supplementing water, and stirring uniformly to obtain the composition.
Example 3
A composition for local anesthesia, which comprises the following substances in percentage by weight: 5% of lidocaine, 5% of prilocaine, 0.35% of menthol, 2.8% of laurocapram, 3% of polyoxyethylene hydrogenated castor oil, 2% of carbomer, and the balance of water.
The preparation method of the composition comprises the following steps:
S1, weighing lidocaine and prilocaine according to a formula, and stirring and melting uniformly at 50-80 ℃ to obtain uniform and transparent liquid, namely eutectic;
S2, weighing carbomer and purified water with the formula amount of 50% according to the formula, standing overnight for swelling to obtain a mixed solution;
S3, adding polyoxyethylene hydrogenated castor oil, menthol and laurocapram with the formula amount into the eutectic mixture in the step S1, stirring and mixing uniformly, and mixing with purified water with the formula amount of 30% at 60-70 ℃ to obtain emulsion for later use;
And S4, adding the mixed solution obtained in the step S2 into the emulsion obtained in the step S3, stirring uniformly, regulating the pH of the solution to 9.2 by using triethanolamine, supplementing water, and stirring uniformly to obtain the composition.
Comparative example
Comparative example 1
This comparative example differs from example 1 in that menthol is not used.
Comparative example 2
This comparative example differs from example 1 in that laurocapram is not used.
Comparative example 3
The difference between this comparative example and example 1 is that the mass ratio of menthol and laurocapram is 0.5:2, wherein the weight percentage of menthol is 0.5% and the weight percentage of laurocapram is 2%.
Comparative example 4
The difference between this comparative example and example 1 is that the mass ratio of active ingredient to penetration enhancer is 7.14:1, wherein the weight percentage of the penetration enhancer is 0.7%, the mass percentage of menthol is 0.03%, and the mass percentage of laurocapram is 0.67%.
Comparative example 5
The product is ground into a raw product, EMLA.
Effect Performance test
Test example 1 percutaneous absorption rate
Evaluation of anesthesia effective time
1.1 Test drug
The compositions of examples 1, 3, and comparative examples 1-5 were locally anesthetized.
1.2 Test animals
(1) Mice (25.+ -.5) g,6-8 weeks old, 42 total, purchased from Peking Vitre Liwa laboratory animal technologies Co.
(2) Animal feeding and experiments are carried out in an animal experiment center of a pharmaceutical institute of China, and the mice can freely obtain drinking water and mouse grains, and the temperature is maintained at 25-26 ℃ and the humidity is maintained at 55-65%. The study was approved by the ethical committee of the animal experiment center of the pharmaceutical institute, zhou, and all animal experimental procedures were performed according to the rules of the chinese animal welfare law.
1.3 Preparation of the labeling curves
0.8000G each of lidocaine and prilocaine was precisely weighed, and the volume was adjusted to 50mL with a phosphate buffer solution of pH7.4 to prepare a stock solution. And (3) respectively taking 0, 0.5, 1.0, 1.5, 2.0 and 3.0mL of stock solution, placing the stock solution into a 50mL volumetric flask, fixing the volume by using a phosphoric acid buffer solution with pH of 7.4, measuring absorbance (A) at a wavelength of 232nm, and performing a linear regression equation on the concentration (c) by using the absorbance to obtain a standard curve equation.
1.4 Preparation of ex vivo skin
The mice are killed by neck breaking, the skin hair of the abdomen is cut off, and the skin hair is peeled off, subcutaneous tissues and fat are removed, the mice are not damaged, and the mice are repeatedly washed by distilled water and then soaked in normal saline for refrigeration for standby.
1.5 Transdermal test
The skin of the mice was fixed between the upper and lower chambers of the modified Franz diffusion cell with the stratum corneum facing upward, 500mg of the local anesthetic composition of example 1, example 3 or comparative examples 1-5 was accurately weighed and uniformly applied to the skin surface, and physiological saline was held in the receiving cell (diffusion area s=3.14 cm 2, volume 18 mL) as a receiving solution, and the receiving solution was just contacted with the dermis layer of the skin. A magnetic stirring rod is arranged in the receiving pool, the receiving pool is placed on a magnetic stirrer, and constant speed is kept at constant temperature (32+/-1 ℃) for continuous stirring. After 10, 30, 60, 120, 240min after the application of the composition, all the receiving solutions were taken out separately, and the same amount of receiving solution was replenished. The absorbance (A) value of the extracted receiving liquid was measured at a wavelength of 232nm, the A value was substituted into a standard curve equation, the sample concentration was calculated, and the cumulative permeation amount was calculated.
TABLE 1 cumulative transdermal absorption penetration (μg/cm 3, mean.+ -. SD, n=6)
Cumulative transdermal penetration results indicate that examples 1 and 3 reached a cumulative transdermal penetration of 40.2130 and 97.4782 μg/cm 3 at 10 minutes and 285.6784 and 566.6987 μg/cm 3 at 240 minutes, indicating that the topical anesthetic compositions of examples 1 and 3 had begun to exert anesthetic effects at 10 minutes and were long lasting to meet the needs of topical anesthesia.
According to the comparison of the data of example 1 and comparative example 1-2, comparative examples 1-2 affected the transdermal absorption rate either by omitting menthol or by omitting laurocapram, and the cumulative transdermal absorption permeation amounts were 33.2456 and 32.4672 μg/cm 3 at 10 minutes, and the anesthetic effect was not exerted until 30 minutes.
According to the comparison of the data of example 1 and comparative example 3, although menthol and laurocapram are used in comparative example 3, the mass ratio of the two is changed, the transdermal absorption rate is deteriorated, the cumulative transdermal absorption penetration amount reaches 46.8972 mug/cm 3 in 30 minutes, and the anesthetic effect is exerted in 30 minutes.
According to the comparison of the data of example 1 and comparative example 4, comparative example 4 changed the mass ratio of active ingredients (lidocaine and prilocaine) to permeation enhancer (menthol and laurocapram), thereby affecting the transdermal absorption rate, resulting in comparative example 4 exerting efficacy at 30 minutes.
Comparative example 5EMLA raw powder the cumulative transdermal absorption penetration reached 37.3030 μg/cm 3 at 30 minutes, and the results indicate that the transdermal absorption rate of example 1 of the present invention is 20 minutes faster than that of comparative example 5.
Test example 2 accelerated stability test
1. Test sample
Examples 1-3 and comparative examples 1-4.
2. Test method
The test sets 7 test groups 1-7, each in parallel, were prepared for the local anesthetic compositions of examples 1-3 and comparative examples 1-4, respectively. The compositions of each test group were placed in a stability test chamber under the following conditions: 40 ℃ + -2 ℃, 75%RH+ -5%RH. Samples were taken at 0, 1 and 3 months, respectively, and the average value of the contents of lidocaine and prilocaine at each sampling point was calculated.
3. Test results
The average content of lidocaine and prilocaine in the accelerated stability test in each test group is shown in tables 2 and 3.
Table 2 average lidocaine content (%) (n=7)
Table 3 average prilocaine content (%) (n=7)
The above results indicate that the compositions of the present invention with local anesthesia do not have a significant decrease in the amounts of the active ingredients lidocaine and prilocaine after the accelerated test. The comparative example showed a significant decrease in the content of lidocaine and prilocaine after 3 months. Thus, the above results indicate that the local anesthetic compositions of the present invention have good stability during storage and meet the quality requirements of long-term storage.
The invention has been further described above in connection with specific embodiments, which are exemplary only and do not limit the scope of the invention in any way. It will be understood by those skilled in the art that various changes and substitutions of details and forms of the technical solution of the present invention may be made without departing from the spirit and scope of the present invention, but these changes and substitutions fall within the scope of the present invention.
Claims (10)
1. A composition for local anesthesia, comprising the following ingredients: an active ingredient and a permeation enhancer;
The active ingredients are lidocaine and prilocaine; the penetration enhancer is at least one of menthol and laurocapram;
The mass ratio of the active ingredient to the penetration enhancer is 0.7-6.8:1.
2. The composition according to claim 1, wherein the penetration enhancer is menthol and laurocapram, and the mass ratio of menthol and laurocapram is (0.02-0.35): (1.5-2.8).
3. The composition of claim 1, wherein the composition comprises 1-5% lidocaine by weight, 1-5% prilocaine by weight, 0.02-0.35% menthol by weight, and 1.5-2.8% laurocapram by weight.
4. The composition of claim 1, further comprising the following materials: emulsifying agent, gelatinizer, pH regulator and water.
5. The composition of claim 4, consisting of the following substances in the weight percentages: 1-5% of lidocaine, 1-5% of prilocaine, 0.02-0.35% of menthol, 1.5-2.8% of laurocapram, 1-3% of emulsifying agent, 0.5-2% of gelling agent, 0.5-5.0% of pH regulator and the balance of water.
6. The composition of claim 4, wherein,
The emulsifier is at least one of polyoxyethylene hydrogenated castor oil, tween, span, polyoxyethylene stearate and polyoxyethylene cetostearyl ether;
the gelatinizer is at least one of carbomer, sodium carboxymethyl cellulose, hypromellose, methylcellulose and chitosan.
7. The composition of claim 4, wherein the pH adjuster is at least one of triethanolamine, triethylamine, ethylenediamine, sodium hydroxide, and sodium bicarbonate, which adjusts the pH of the composition to 8.5-10.
8. A process for the preparation of a composition as claimed in any one of claims 1 to 7, comprising the steps of:
s1, weighing lidocaine and prilocaine, and melting to obtain a eutectic;
S2, weighing a gelatinizing agent, adding water, and stirring and swelling completely to obtain a mixed solution for later use;
S3, adding an emulsifier, menthol, laurocapram and water into the eutectic mixture in the step S1, and uniformly mixing to obtain emulsion for later use;
S4, adding the mixed solution and the pH regulator in the step S2 into the emulsion in the step S3, regulating the pH to 8.5-10, supplementing water, and uniformly mixing to obtain the composition.
9. Use of a composition according to any one of claims 1 to 7 or a composition prepared by a method of preparation according to claim 8 for the preparation of a medicament for local anaesthesia.
10. A medicament for local anesthesia, characterized by comprising a composition according to any one of claims 1 to 7 or a composition prepared by the preparation method according to claim 8.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311825575.2A CN117919214A (en) | 2023-12-27 | 2023-12-27 | Penetration-promoting local anesthetic composition and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311825575.2A CN117919214A (en) | 2023-12-27 | 2023-12-27 | Penetration-promoting local anesthetic composition and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117919214A true CN117919214A (en) | 2024-04-26 |
Family
ID=90765487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311825575.2A Pending CN117919214A (en) | 2023-12-27 | 2023-12-27 | Penetration-promoting local anesthetic composition and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117919214A (en) |
-
2023
- 2023-12-27 CN CN202311825575.2A patent/CN117919214A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4695465A (en) | Soft patch | |
| EP3536380B1 (en) | Rapid-acting insulin compositions | |
| EP1946763A1 (en) | Promoter for recovery from anesthesia | |
| CN112439054B (en) | Teriparatide sustained-release gel injection and preparation method thereof | |
| DE4212640A1 (en) | STABLE DRUG COMPOSITIONS CONTAINING BETABLOCKER WITH REGULATED ACTIVE SUBSTANCE DELIVERY FOR ORAL ADMINISTRATION AND METHOD FOR THE PRODUCTION THEREOF | |
| KR20100017183A (en) | Body-temperature lowering depressant | |
| CN102657602B (en) | 3,5-dyhydroxyl-4-isopropyl diphenylethene chitosan gel and preparation method thereof | |
| CN117919214A (en) | Penetration-promoting local anesthetic composition and preparation method and application thereof | |
| JPS60239421A (en) | Local blended drug for accelerating wound granulation and epithelial formation and manufacture | |
| EP3984524A1 (en) | Ornidazole injection and s-ornidazole injection | |
| CN112704662B (en) | Lidocaine emulsifiable paste, preparation method and application thereof | |
| RU2699674C1 (en) | Percutaneous absorption composition | |
| CN109528693B (en) | Rapamycin cataplasm and preparation method thereof | |
| JPH02191212A (en) | Infusion solution preparation comprising 3-hydroxybutyric acid (beta-hydroxybutyric acid) and slat thereof | |
| CN108210929A (en) | A kind of pharmaceutical composition containing Etoricoxib and preparation method thereof | |
| CN112263544A (en) | Lidocaine hydrochloride gel and preparation method thereof | |
| CN113018254A (en) | Ibuprofen liquid crystal gel transdermal preparation for treating primary dysmenorrhea and preparation method thereof | |
| Ardente et al. | Vehicle effects on in vitro transdermal absorption of sevoflurane in the bullfrog, Rana catesbeiana | |
| RU2736081C1 (en) | Transdermatic plaster with glycazide | |
| CN110898042B (en) | Salbutamol sulfate solution for inhalation and preparation method thereof | |
| CN114504549B (en) | Aqueous gel of biotin and preparation method and application thereof | |
| CA2796567A1 (en) | Composition comprising insulin and herbal oil for transdermal or transmucosal administration | |
| CN114712264B (en) | Synergistic stable sodium hyaluronate composite solution composition and preparation thereof | |
| CN112439071B (en) | Transdermal penetration-promoting composition and application thereof in timolol preparation | |
| RU2429818C1 (en) | Therapeutic agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |